ABSTRACT BACKGROUND Long QT syndrome (LQTS) is a potentially lethal cardiac channelopathy with a 1% to 5% annual risk of
L ong QT syndrome (LQTS) is one of the most common cardiac channelopathies that predisposes patients to arrhythmogenic syncope, seizures, and sudden cardiac death (SCD) (1) (2) (3) . Clinical expressivity of LQTS ranges from a lifelong asymptomatic state with no electrocardiographic findings (i.e., concealed LQTS) to frequent, recurrent LQTStriggered torsades culminating in SCD (4, 5) .
Despite numerous genotype-phenotype correlation studies, the extreme variance in expressivity makes it difficult for the patient and the physician to accurately predict the chance of experiencing an LQTS-related breakthrough cardiac event (BCE).
Current knowledge regarding treated and untreated cardiac event rates in patients with LQTS stems from initial retrospective and prospective studies from international LQTS registry data, or small, single-center studies generally evaluating a specific treatment (e.g., beta-blockers and left cardiac sympathetic denervation [LCSD] ). It has been reported that untreated asymptomatic patients with genotyped LQTS have a high risk of any cardiac event and SCD (36% and 13%, respectively, in a 28-year follow-up) (6) . As first shown in 1985, beta-blockers drastically reduced mortality (from event rates ranging from as high as 71% in previously untreated symptomatic patients to 6% in patients on therapy), and for these past 30 years beta-blocker therapy has been the initial treatment of choice (7) . Recent studies have focused mostly on evaluating outcomes of single-treatment modalities. Beta-blockers (chiefly nadolol and propranolol) reduce mortality to approximately 0.5% to 2% during a follow-up of 5 to 10 years (8, 9) . However, despite this significant decrease in mortality, beta-blocker-treated LQTS patients continue to have an annualized BCE rate of around 3% (8, 9) . For those patients with recurrent BCEs despite pharmacotherapy, LCSD significantly reduces the number of BCEs (10) (11) (12) .
Given that our current outcome estimates are derived mostly from multicenter or registry-based studies, we sought to evaluate the outcomes of patients with congenital LQTS who were evaluated and treated in single specialty center dedicated to patients with genetic heart rhythm diseases such as LQTS.
METHODS
We performed a retrospective review of the electronic medical records of 606 patients who were evaluated This data as well as the frequency of each type of BCE observed is summarized in Online Table 1 . The breakdown of event burden before and after the patients' Mayo Clinic evaluation and treatment are described and shown in Figure 2 . As a tertiary care center, 158 (26%) patients had been referred from an outside institution for further treatment guidance after the LQTS diagnosis had been determined and initial treatment for LQTS had already commenced.
Outcomes in LQTS
Among this physician-referred subset, 70 (44%) patients were symptomatic prior to diagnosis. Among all 166 previously symptomatic patients, 125 (75%) realized a significant decrease in event burden.
Conversely, 42 (25%) of these patients experienced subsequent LQTS-triggered BCEs.
Overall, the BCE-free survival was 96% at 1 year, 93% at 5 years, and 90% at 10 years for the entire cohort ( Figure 3A) . In fact, there were only 2 LQTSrelated deaths (w0.3% overall, 1% among previously Abbreviations as in Table 1 . symptomatic patients) (Online Table 2 ) and 3 (<0.5%) heart transplants in over 4,000 collective years of treated follow-up (14) . Demographics and clinical details for these 5 cases are summarized in Online Figure 3B ). There were no significant differences between treated follow-up years between asymptomatic and symptomatic patients. who succumbed subsequently to SCD were among these 27 patients who presented before 1 year of age.
As beta-blockers have been the gold standard of LQTS-directed pharmacotherapy, we further analyzed if there was a sex-specific risk associated with treatment outcomes. In our cohort of patients treated by a single LQTS specialist, we did not see evidence of a sex-specific effect of beta-blockers, even when subdividing by genotype (Online (2) 12 (7) 2-5 BCEs 21 (3) -21 (13) 6-10 BCEs 6 (1)
Values are median (interquartile range), n/N (%), or n (%) unless otherwise indicated. *The incidence of a patient with any breakthrough cardiac event (BCE) per yr.
in Figure 3C . One-year and 10-year BCE-free survival was highest in patients with LQT1 (98% and 95%, respectively), whereas 1-year BCE-free survival was lowest in patients with LQTM (86% and 74%, respectively). Treated follow-up duration was similar between all LQTS genotypes. Here, in our patient-tailored treatment program, we report an extremely low mortality of 2 of 606 (0.3%) 
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Values are median (interquartile range) or n (%), unless otherwise indicated. *Bonferroni correction was used to reduce type I error. †The incidence of a patient with any breakthrough cardiac event (BCE) per year. ‡These patients were excluded from statistical analysis. Bold indicates significant findings.
Abbreviations as in Table 1 . BCEs than previously reported: 99% BCE-free survival at 5 years among asymptomatic patients in this study compared with 94% from a prior study, and 77% BCE-free survival at 5 years among previously symptomatic patients in this study compared with 68% from a prior study (8) .
Akin to previous observations, our cohort also suggests strong genotype-specific risk for recurrent BCEs. Our data show that patients with LQT3 and patients with LQTM are at highest risk of BCEs when compared with LQT1 and LQT2 patients (17) .
However, even among these genotypic higher-risk subsets, overall improvements in BCE-free survival when compared with historical cohorts are seen.
This study sheds light on number of important facets of outcomes in patients with LQTS in the contemporary era. First, LQTS-associated mortality should be rare. Mortality has significantly decreased in appropriately risk stratified and treated LQTS patients, even with the majority of patients being treated without an ICD. Second, the incidence of LQTS-related BCEs in patients treated at a single LQTS specialty center is less than previously reported, whether looking at the cohort as a whole, divided by symptomatic status, or by genotype (Central Illustration). Third, compared with previous studies, the majority of patients in our cohort were diagnosed while asymptomatic (73% vs. 36% to 53%), which may be evidence of the changing landscape of LQTS in the contemporary era (8, 16 
